Deciphera Pharmaceuticals Inc (DCPH) Has a New Rating from H.C. Wainwright

By Jason Carr

H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on Deciphera Pharmaceuticals Inc (DCPHResearch Report) today and set a price target of $60.00. The company’s shares closed last Monday at $34.15.

According to TipRanks.com, Fein ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.6% and a 36.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Deciphera Pharmaceuticals Inc with a $50.18 average price target, a 52.8% upside from current levels. In a report issued on September 30, Jefferies also initiated coverage with a Buy rating on the stock with a $47.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $42.99 and a one-year low of $18.55. Currently, Deciphera Pharmaceuticals Inc has an average volume of 762.9K.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DCPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.